Can brepocitinib improve remission in skin condition?
-
By
-
Andrea Surnit
-
November 13, 2026
-
4 min
By
Andrea Surnit
November 13, 2026
A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.
by Kerri Miller
April 16, 2026
A single case report described possible lichen planus pigmentosus inversus following tirzepatide initiation.
May 7, 2026
Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.
April 28, 2026